GlassScriptPhysician profile
Asokumar Buvanendran
NPI 1598781676
$51,857.57
in general payments reported to CMS, 2019-2025
16 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $13K · 2021: $9,478 · 2022: $2,816 · 2023: $759 · 2024: $11K · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,688 · Food and Beverage: $2,498 · Travel and Lodging: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,688.00 |
| Food and Beverage | $2,497.77 |
| Travel and Lodging | $1,441.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $20,996.59 | 2021-2024 | |
| Grt US Holding, INC. | $8,000.00 | 2020 | |
| Medtronic USA, INC. | $7,302.60 | 2019-2020 | |
| Abbott Laboratories | $5,149.83 | 2019-2025 | Eterna, Proclaim |
| Fresenius Kabi USA, LLC | $5,006.19 | 2019-2025 | Dilaudid |
| Pfizer INC. | $3,780.00 | 2020 | |
| Medtronic, INC. | $729.03 | 2021-2022 | |
| Edwards Lifesciences Corporation | $450.00 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $121.10 | 2019 | |
| Nevro Corp. | $118.07 | 2019 | |
| Heron Therapeutics, INC. | $75.23 | 2023 | Zynrelef |
| Spr Therapeutics, INC | $57.58 | 2021 | |
| Smiths Medical Asd, INC. | $33.82 | 2019 | |
| Avanos Medical | $19.67 | 2019 | |
| Curonix LLC | $17.86 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asokumar Buvanendran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.